Gide advises biopharmaceutical Inventiva on $172.5 million US ADS offering

Gide and other firms advised the parties to the transaction: Gide advised biopharmaceutical company Inventiva in connection with the US offering; Cooley LLP advised Inventiva on US law matters; Davis Polk advised the banks, including Piper Sandler & Co. and Leerinck Partners LLC, on US law matters; and CMS Francis Lefebvre advised the banks on French law matters. The transaction consisted of a public offering in the United States of American Depositary Shares (ADS) for a total amount of $172.5 million. The offering was represented by approximately 44.8 million ADS following the full exercise of the overallotment option. This capital raise complements a previously agreed financing package of up to €348 million, concluded in October 2024 and composed of several firm or conditional tranches. Inventiva, a biopharmaceutical company listed on Euronext Paris and Nasdaq that develops oral therapies for metabolic dysfunction–associated steatohepatitis (MASH), expects main results from its Phase 3 NATiV3 study in the second half of 2026. Gide represented Inventiva with a team composed by: Arnaud Duhamel, partner; Aude-Laurène Dourdain, counsel; Elise Raymond and Marie des Neiges Paupe, associates, capital markets. Cooley LLP represented Inventiva with a team composed by: Cooley LLP US counsel advising on US law matters. Davis Polk represented the banks, including Piper Sandler & Co. and Leerinck Partners LLC, with a team composed by: Davis Polk US counsel advising the banks on US law matters. CMS Francis Lefebvre represented the banks with a team composed by: CMS Francis Lefebvre French counsel advising the banks on French law matters.

Gide advises biopharmaceutical Inventiva on $172.5 million US ADS offering

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads